HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals Plc, a clinical-stage biopharmaceutical company, will present its proprietary Chimeric Bait Receptor (CBR) platform at the upcoming 6th Macrophage-Directed Therapies Summit in Boston. Their CBR platform targets the programming of immune cells to attack specific cancers and viral infections. The presentation aims to solidify the company’s standing in myeloid cell therapy and foster collaboration and investment opportunities.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
